Evidence map›Paper›PMID 41400804›Full record

ArticleAnnals of surgical oncology2026

Outcome Analysis of Cytoreductive Surgery and Hyperthermic Intrathoracic Chemoperfusion (HITHOC) for Pseudomyxoma Peritonei with Pleural Metastasis.

Edra Ha, Yota Suzuki, Inderpal S Sarkaria, Victor Crentsil, Olugbenga Okusanya, James D Luketich, Omar Awais, M Haroon A Choudry, Neil A Christie

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Edra Ha *University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Yota Suzuki *Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. rsr2ys@gmail.com.ORCID http://orcid.org/0000-0003-4967-1625
Inderpal S SarkariaDepartment of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Victor CrentsilDepartment of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Olugbenga OkusanyaDepartment of Surgery, Thomas Jefferson University Kimmel Medical College, Philadelphia, PA, USA.
James D LuketichDepartment of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Omar AwaisDepartment of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
M Haroon A ChoudryDepartment of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Neil A ChristieDepartment of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough cytoreductive surgery (CRS) and hyperthermic intrathoracic chemoperfusion (HITHOC) are used to treat primary pleural malignancies, their role in managing pleural metastases from pseudomyxoma peritonei (PMP) remains underexplored. This study evaluated the role of CRS/HITHOC on outcomes of PMP with pleural involvement. PATIENTS AND

methodsWe conducted a single-institution, retrospective analysis of patients with PMP who underwent CRS/hyperthermic intraperitoneal chemotherapy (HIPEC) between 2008 and 2022. Perioperative and oncologic outcomes between patients with metachronous or synchronous pleural metastases were compared between those treated with and without CRS/HITHOC.

resultsA total of 814 patients with PMP underwent CRS/HIPEC during the study period. In total, 64 patients (7.9%) developed pleural metastases (8 synchronous and 56 metachronous), with a median pleural recurrence interval of 15.6 months (interquartile range (IQR) = 6.8-26.6 months). Of these, 20 patients received CRS/HITHOC as part of multimodal management. There was no significant difference in median age between groups (52 versus 56 years; p = 0.602), though the CRS/HITHOC group trended toward fewer preceding recurrences at other sites (35.0% versus 43.2%; p = 0.593). All 20 patients undergoing HITHOC had pleurectomy and decortication; there was no 30-day mortality. The HITHOC group demonstrated a trend toward improved OS after pleural recurrence (58.5 versus 16.4 months; p = 0.063) and had a longer survival from the time of initial HIPEC (106.0 versus 42.9 months; p = 0.015) in this cohort.

conclusionsIncorporating HITHOC into the management of PMP with pleural involvement was associated with improved survival and may represent an effective strategy for both the treatment and palliation of pleural metastases in PMP.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChemotherapy, Cancer, Regional PerfusionCytoreduction Surgical ProceduresHyperthermia, InducedHyperthermic Intraperitoneal ChemotherapyPeritoneal NeoplasmsPleural NeoplasmsPseudomyxoma PeritoneiAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedCytoreductive surgeryHyperthermic intrathoracic chemoperfusionPseudomyxoma peritonei

Identifiers

PMID41400804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.